Professor Ian McKeith leads research that resulted in the first diagnosis and treatment of DLB.
Dementia devastates the lives of 36 million people worldwide and costs $315 billion in healthcare, and DLB is now known to be the second most frequent cause of degenerative dementia after Alzheimer’s disease.
Little more than a decade ago the disease was relatively unknown and those affected by it were often treated with drugs that could worsen their unpleasant symptoms, or even prove fatal.
Until the team at Newcastle University developed a new brain imaging technique to identify DLB, the mental symptoms of sufferers – such as memory loss and confusion – were often mistaken for Alzheimer’s disease, while the motor symptoms, including gait and slowness of movement, were mistaken for Parkinson’s disease.
Alistair Burns, National Clinical Director for Dementia commented "The basic science and cutting-edge translational research carried out at Newcastle University highlighted the benefits of diagnosis of DLB and of the cholinesterase drugs, each of which has had significant influence on clinical practice."
The breakthrough came when the team identified that cholinesterase inhibitors (CHEIs), a class of drug originally developed for use in Alzheimer’s disease, would be of greater benefit in DLB and also in Parkinson’s disease dementia.
The research has been published in:
- The Lancet
- The Lancet Neurology
CHEIs are now recommended in national and international guidelines for the cognitive and psychiatric symptoms associated with both of these conditions which previously had no effective treatment.
Professor McKeith explains: “The DaTSCAN brain imaging technique developed in collaboration with GE Healthcare for use in dementia diagnosis, and the class of drug that we were the first to test in a large, placebo-controlled, randomised trial, are now in use around the world.
These have revolutionised the lives of patients. For the first time, we are able to manage symptoms such as cognitive failure, hallucinations, apathy and anxiety.
We have come a long way in our understanding of this debilitating and distressing condition. The momentum we have created has enabled us to establish world class facilities at Newcastle University. In collaboration with other international groups, we are now using our tissue resource to investigate why brain cells become dysfunctional. We are also planning to take part in the first trials to arrest the disease process.”
- Read about Professor Ian McKeith’s profile, research interests and publications
- In his role as President of the UK charity Lewy Body Society, Professor McKeith explains in a video about advances in research and clinical practice
- Read more about the Institute for Ageing
Professor Ian McKeith
Telephone: +44 (0) 191 208 1313
How You Can Help
Find out how you can support our research.